Remedia
Farmaceutica REMEDIA S.A.



3rd Quarter 2026 CONSOLIDATED REPORT

Board of Administrators of
Farmaceutica REMEDIA S.A.

Farmaceutica REMEDIA S.A.
Registered office: Deva 330040, Nicolae Balcescu Bld. no 2 (former No. 43 Dorobantilor Street), Hunedoara County, Telephone: + 40 254 223 260, Fax: +40 254 226 197
Branch office: Bucharest, 041836, sector 4, Bld. Metalurgiei 78, Telephone/fax: + 40 213 211 640
remedia@remedia.ro, www.remedia.ro
Trade Register J1991000700203, TIN: RO2115198; Share capital: RON 9.548.082
IBAN: RO61 BTRL RONC RT00 G713 3302, Transilvania Bank, Bucharest
IBAN: RO33 RZBR 0000 0600 0266 5747, Raiffeisen Unirii, Bucharest

3rd QUARTER 2026 CONSOLIDATED REPORT
According to F.S.A. Regulation No. 5/2018

Date of the report: 18.11.2026

Name of the commercial company: **Farmaceutica REMEDIA S.A.**

Subscribed share capital: **9.548.082 Lei**
Paid-up share capital: **9.548.082 Lei**
Registered office: **DEVA, No. 2 Nicolae Bălcescu Bd.**, pc **330160**
Tel./fax.: **+40 254 223 260, +40 254 226 197**
No. and date of registration with the Trade Register Office: **J1991000700203**
Tax registration number: **RO2115198**

Securities: **RMAH shares**
(**Registration certificate No. AC-1470-7/17.06.2021**)
Type: **Common Nominative**
Date of registration: **17.03.1997**
Nominal value: **0,10 Lei**
Position in RNSC Register: **1636**
Total number: **95.480.820**
R.N.S.C. code of shares: **16368**

Registration	Date	Number of shares	Issue value
1	10.11.1999	3.370.107	337.010.70 Lei
2	06.09.2001	1.500.000	150.000,00 Lei
3	23.07.2003	42.402	4.240,20 Lei
4	05.01.2006	5.696.471	569.647,10 Lei
5	21.12.2007	87.905.969	8.790.596,90 Lei
6	08.04.2009	7.574.851	757.485,10Lei
7	09.06.2021	- 10.608.980	- 1.060.898,00 Lei
	TOTAL	**95.480.820**	**9.548.082,00 Lei**

Organised market on which securities are traded:
Bucharest Stock Exchange – Standard category
The total market value on 18.11.2026 is of 77.912.349 Lei, at a value of a 0,816. Lei/RMAH share

1. Important events to report

During the reporting period, Remedia completed the installation of two pharmacy robots in Jibou and Beius. As a result, the company's own technical team has now installed and commissioned a total of 26 units, consolidating the company's position as the national leader in the automation of pharmacies, warehouses and hospital facilities.

In July 2026, Remedia signed a market maker contract with IFB Finwest SA, with the aim of increasing the liquidity of financial instruments by facilitating buying and selling transactions at a reduced spread, and of enhancing the visibility and attractiveness of the financial instrument to investors.

2. The general description of the financial position and of the issuer's performances and of its branches related to 3rd quarter 2026

During 01.01.2026 – 30.09.2026, the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations Jan-Sept 2026 (Lei)	Realisations Jan-Sept 2025 (Lei)	Evolution 2026/2025 (%)
1.	Net sales of goods *	530.640.205	545.548.120	-2,73%
2.	Other operating revenues	6.207.579	7.755.423	-19,96%
3.	Total operating income	536.847.784	553.303.543	-2,97%
4.	Total operational costs *	532.725.586	541.956.492	-1,70%
5.	Operating result	4.122.198	11.347.051	-63,67%
6.	Financial result	1.465.058	861.278	70,10%
7.	Gross result	**5.587.256**	**12.208.329**	-54,23%

* Including trade discounts granted/received

A breakdown of sales of goods by segments of activity is presented as follows:
Lei

REMEDIA Pharmacies	7.623.332	1,4%
Distribution	373.630.716	70,4%
Hospitals & Clinics Distribution	148.231.137	28%
BD Rowa robots	1.155.018	0,2%
Total	**530.640.205**	**100,00 %**

"Other operating revenues" mainly comprise the following categories of revenues:

- collected rents

- BD Rowa services
- other services
- other operating income

3. The financial statements as of 30.09.2026 were not audited by the independent financial auditor.

4. Economic-Financial Indicators as of 30.09.2026

LIQUIDITY AND WORKING CAPITAL	**FR**	**FRDL**
Current liquidity (Current assets / Current debts)	7,92	1,05
Current assets	19.048.753	283.621.093
Current debts	2.404.962	270.439.890
Degree of indebtedness (Borrowed capital / Equity x 100)	**0,00%**	**0%**
Borrowed capital	0	0
Equity	58.151.695	20.048.652
Turnover speed for client debit items (Average customer balance /turnover *270)	**116 days**	**97 days**
Average customer balance	2.758.567	190.792.977
Net turnover	6.426.710	532.679.764
Turnover speed of stocks (average stock/ net COGS)*270	**55 days**	**30 days**
Average stock	242.139	53.636.365
COGS net	1.191.862	490.198.841

*including financial leasing

Notes:

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the companies are able to cover their short-term debts based on receivables and cash availabilities.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of the FR & FRDL there is no risk.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of the indicator is normal, under the circumstances. In the case of the companies in the group the indicator shows a good collection of receivables.

4) The value of the **No. of storage Days** indicator can be considered as falling within the specifics of the activity.

18.11.2026

Board of Administrators
Chairman
"TARUS" Valentin-Norbert TARUS e.U.
1020 Viena, Leopold-Moses Gasse, 4/42/6, Austria

FN 349134h/23.07.2010

Farmaceutica REMEDIA SA

STATEMENT OF COMPREHENSIVE INCOME - consolidated (Lei)

	30.09.2026	30.09.2025
Net turnover	**536.579.265**	**551.099.586**
Income from the sale of goods	532.485.297	547.588.341
Commercial discounts granted	-1.845.092	-2.040.222
Income from services provided and rents	5.939.060	5.551.466
Income from real estate investments		**0**
Other operating income	**268.519**	**2.203.957**
OPERATING INCOME - TOTAL	**536.847.784**	**553.303.543**
Expenses with materials	**493.328.808**	**506.375.911**
Expenses regarding goods	512.026.980	519.008.208
Commercial discounts received	-20.834.931	-14.589.226
Expenses with raw materials and consumables	1.274.569	1.122.380
Other expenses with materials (inventory objects)	117.221	97.970
Energy and water expenses	744.970	736.578
Expenses with personnel	**19.451.310**	**18.447.530**
Salaries and allowances	16.558.761	15.811.245
Expenses with insurance and social protection	575.558	891.884
Other personnel expenses	2.316.991	1.744.401
Amortisations and provisions	**2.131.878**	**1.324.613**
Amortisations	2.046.404	1.727.818
Net provisions	-37.184	-681.393
Losses from receivables	122.658	278.187
Other operating expenses	**17.813.590**	**15.808.438**
Expenses on external services	15.570.746	13.170.382
Expenses with other taxes, charges and assimilated payments	1.839.219	1.514.182
Other expenses	403.624	1.123.874
OPERATING EXPENSES - TOTAL	**532.725.586**	**541.956.492**
OPERATING RESULT	**4.122.198**	**11.347.051**
Financial income	**1.805.241**	**1.326.398**
Interest income	1.121.134	936.468
Income from exchange rate differences	257.417	190.929
Income from dividends	78.468	0
Advance payment discounts	65.210	162.547
Other financial income		
Other financial revenues share of the loss from investments accounted for using the equity method	283.012	36.453
Financial expenses	**340.183**	**465.120**
Expenses regarding interests leasing	0	0
Operational leasing interests	30.859	34.775
Expenses due to exchange rate differences	309.324	430.346
Discounts received in advance	0	0
Other financial expenses	0	0
Other financial expenses - share of the loss from investments accounted for using the equity method	0	0
FINANCIAL RESULT	**1.465.058**	**861.278**

TOTAL INCOME	**538.653.025**	**554.629.941**
TOTAL EXPENSES	**533.065.769**	**542.421.612**
GROSS RESULT	**5.587.256**	**12.208.329**
Profit tax	2.713.878	5.647.224
TOTAL NET PROFIT of which distributable	**2.873.379**	**6.561.104**
Shareholders of the company	**2.873.379**	**6.561.104**
Minority interest		
Other elements of comprehensive income		
Revaluation of tangible assets		
Tax related to other elements of comprehensive income		
Minority interest		
COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of which attrib	**2.873.379**	**6.561.104**
Shareholders of the company	**2.873.379**	**6.561.104**
Minority interest		
Earnings per share (in Lei)		
- basic	0,0301	0,0687
- diluted	0,0301	0,0687

* retreated according to IFRS 16

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin – Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF FINANCIAL POSITION - consolidated (Lei)

	30.09.2026	31.12.2025
ASSETS		
Fixed assets	**51.964.540**	**51.617.337**
Tangible assets	31.805.711	31.180.789
Real estate investments	17.778.668	17.778.668
Assets related to the rights of use of leased assets	460.871	710.173
Software licences	898.008	1.028.279
Pharmacy licences	197.813	424.520
Participations held in group companies	0	0
Participations held in companies outside the group	130.286	130.286
Investments in jointly controlled entities accounted for using the equity method	447.967	164.955
Deposits and guarantees paid	245.216	199.668
Current assets	**301.535.075**	**331.298.467**
Stocks	52.284.044	63.371.504
Advances granted for the purchase of stocks	3.336	2.063
Trade receivables	196.113.976	205.038.726
Other receivables	6.459.891	4.947.298
Cash and cash equivalents	46.673.828	57.938.876
Accrued expenses	**428.822**	**269.736**
TOTAL ASSETS	**353.928.437**	**383.185.541**
EQUITIES AND DEBTS		
Equities	**76.928.690**	**79.610.034**
Share capital	9.548.082	9.548.082
Share premiums	757.485	757.485
Reserves	20.099.711	17.726.280
Revaluation reserves	30.526.555	30.526.555
Current result	2.873.379	8.038.123
Retained earnings	18.196.464	18.881.235
Retained earnings - retreatment	-557.383	-775.278
Profit distribution	0	0
Own shares	-1.316.108	-1.316.108
Losses related to the issuance, redemption, sale, free transfer or cancellation of equity instruments	-107.727	-107.727
Employee benefits in the form of equity instruments	645.553	68.708
Other equity items	-3.737.321	-3.737.321
Long-term debts	**5.213.331**	**5.213.138**
Debts from long term operational leasing	416.855	416.662
Provisions		
Debts with deferred income tax	4.796.476	4.796.476
Current debts	**271.786.416**	**298.362.368**
Bank loans		
Debts from financial leasing		
Debts from operational leasing	77.092	333.866
Suppliers and other similar debts	265.365.533	291.624.623
Provisions	0	562.278
Current tax debts	1.031.407	2.369.475

Other short-term debts	5.056.795	3.216.538
Deferred income tax liabilities	255.588	255.588
Total debts	**276.999.747**	**303.575.506**
TOTAL EQUITIES AND DEBTS	**353.928.437**	**383.185.540**

* retreated according to IFRS 16

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin – Norbert TARUS

NOTE 1 INFORMATION ABOUT THE COMPANY

Farmaceutica REMEDIA S.A. (« the Company ») is a commercial company with registered office in Deva, No. 2 Nicolae Balcescu Bld. (former Str. Dorobantilor 43), Hunedoara County, Romania.

On **July 25th 1991**, it was established as a commercial company with fully state-owned capital by reorganisation of Oficiul Farmaceutic Deva.

On **October 13th 2000**, V. TARUS RoAgencies S.R.L. purchased from FPS the majority shares package (55,802%).

On **January 1st 2006**, Farmaceutica REMEDIA S.A. merged by absorption with V. TARUS RoAgencies S.R.L.

According to Law 95/2006, republished in August 2015, companies were prohibited from carrying out, at the same time, wholesale and retail distribution of medicines. (Art. 800 paragraph 2). Therefore,

On **January 1st 2016** Farmaceutica REMEDIA S.A. completed the transfer to Farmaceutica REMEDIA Distribution & Logistics S.R.L., a new company, 100% owned, of the wholesale distribution activities of medicines together with related activities (logistic services, registration of pharmaceutical products, promotion and marketing of medicines, etc.), Farmaceutica REMEDIA S.A. kept the operation of the chain of pharmacies and local offices.

In **April 2022**, Farmaceutica REMEDIA SA purchased a 50% participation in the share capital of the Romanian legal entity PHARMA EXPERTSPEDITION S.R.L., with registered office in Bucharest, Bd. Metalurgiei, nr. 130E, Sector 4, registered at the Commercial Register of Bucharest with nr. J40/20206/2005, with TIN 18178346, in order to develop and strengthen the distribution and logistics activity.

In **January 2025**, Farmaceutica REMEDIA SA (FR) acquired 24 per cent of the share capital of SC Novoengrama SRL, a company specialising in medical rehabilitation, which operates in the city of Cluj-Napoca.

In this context, **on 30.09.2026** Farmaceutica REMEDIA S.A. held a majority participation (100%) in the company Farmaceutica REMEDIA Distribution & Logistics S.R.L. and a 50% participation in the company PHARMA EXPERTSPEDITION S.R.L.

During the first nine months of 2026 Farmaceutica REMEDIA S.A. did not participate in mergers.

During the same period, the company did not alienate assets of significant value (buildings, land, shares, etc.).

During the reporting period, Remedia completed the installation of two pharmacy robots in Jibou and Beius. As a result, the company’s own technical team has now installed and commissioned a total of 26 units, consolidating the company’s position as the national leader in the automation of pharmacies, warehouses and hospital facilities.

In July 2026, Remedia signed a market maker contract with IFB Finwest SA, with the aim of increasing the liquidity of financial instruments by facilitating buying and selling transactions at a reduced spread, and of enhancing the visibility and attractiveness of the financial instrument to investors.

NOTE 2 BASES FOR DRAFTING THE FINANCIAL STATEMENTS

The financial statements of the company were drafted in compliance with the provisions of Order No. 2844/2016 for the approval of the Accounting regulations in compliance with the International Financial Reporting Standards (IFRS), adopted by the European Union, applicable to commercial companies whose securities are

admitted to trading on a regulated market, with all subsequent modifications and clarifications.

For the purpose of drafting these financial statements, in compliance with the legislative provisions in Romania, the functional currency of the company is considered to be the Romanian Leu (RON).

For all the periods until the year concluded on 31 December 2011, inclusive, the company prepared the financial statements in compliance with the Romanian Accounting Standards (RAS). The financial statements for the year concluded on 31 December 2012, are the first financial statements drafted in compliance with the International Financial Reporting Standards (IFRS), as adopted by the European Union.

The financial statements were drafted based on the historic cost, except for the buildings and lands which are assessed at their fair value (the market value determined by assessment by an expert evaluator). The historic cost is generally based on the fair value of the counter-performance carried out in exchange for the assets.

The company presents in the financial statements at the fair value all the asset and passive elements for which the assessment at the fair value is imposed, the methods used for its establishment being inventory and revaluation (IFRS 13).

The company does not have financial statements which would involve the use of other fair value estimation methods.

Certain amounts from the financial position statement, the global result statement, as well as from the explanatory notes were reclassified to ensure comparability between previous years and the current year.

Preparation of the IFRS financial statements involves the use by the management of professional judgments, estimations and hypotheses that may affect the application of the accounting policies and the reported value of assets, debts, incomes and expenses. Under these conditions, the actual results may differ from the estimated values. Estimates and hypotheses that are based on them are periodically reviewed. The review of accounting estimates is recognised during the period in which the estimate was reviewed and in the future periods affected. The following are critical professional judgments / reasoning which the Company management made with a significant impact on the values recognized in the financial statements:

- Lifespan of fixed assets
- Deferred taxes
- Provisions
  Segment reporting
- Retreatment of operational leasing contracts according to IFRS 16

The company holds participations in other companies, in one of them having the control over the financial and operational policies. An entity is consolidated if, based on the assessment of its relations with the Company, it is found that it is controlled by the Company.

The companies whose financial statements are consolidated are:

- Farmaceutica REMEDIA S.A.
- Farmaceutica REMEDIA Distribution & Logistics S.R.L.
- PHARMA EXPERTSPEDITION SRL, a company in which **Farmaceutica REMEDIA S.A. holds 50% of the share capital, using the equity method**

Starting with 2012, for the class of tangible assets « Lands and buildings », the Company passed from the cost-based accounting model to the reassessment model.

The consolidated financial statements on 30.09.2026 were not audited by the independent financial auditor.

NOTE 3 SALES REVENUES AND OTHER OPERATING REVENUES

During the period 01.01.2026 – 30.09.2026, the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations Jan-Sep 2026 (Lei)	Realisations Jan-Sep 2025 (Lei)	Evolution 2026/2025 (%)
1.	Net sales of goods *	530.640.205	545.548.120	-2,73%
2.	Other operating revenues	6.207.579	7.755.423	-19,96%
3.	Total operating revenues	536.847.784	553.303.543	-2,97%
4.	Total operating costs *	532.725.586	541.956.492	-1,70%
5.	Operating result	4.122.198	11.347.051	-63,67%
6.	Financial result	1.465.058	861.278	70,10%
7.	**Gross result**	**5.587.256**	**12.208.329**	-54,23%

* Including trade discounts granted/received

A breakdown of goods sales by business segment is as follows:

REMEDIA Pharmacies	7.623.332	1,4%
Distribution	373.630.716	70,4%
Hospitals & Clinics Distribution	148.231.137	28%
BD Rowa robots	1.155.018	0,2%
Total	**530.640.205**	**100,00 %**

"Other operating revenues" mainly comprise the following categories of revenues:

- collected rents
- BD Rowa services

- other services
- other operating revenues

NOTE 4 ECONOMIC-FINANCIAL INDICATORS

LIQUIDITY AND WORKING CAPITAL	FR	FRDL
Current liquidity (Current assets / Current debts)	7,92	1,05
Current assets	19.048.753	283.621.093
Current debts	2.404.962	270.439.890
Degree of indebtedness (Borrowed capital / Equity x 100)	**0,00%**	**0%**
Borrowed capital	0	0
Equity	58.151.695	20.048.652
Turnover speed for client debit items (Average customer balance /turnover *270)	**116 days**	**97 days**
Average customer balance	2.758.567	190.792.977
Net turnover	6.426.710	532.679.764
Turnover speed of stocks (average stock/ net COGS)*270)	**55 days**	**30 days**
Average stock	242.139	53.636.365
COGS net	1.191.862	490.198.841

*including financial leasing

Notes:

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the companies are able to cover their short-term debts based on receivables and cash availabilities.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of the FR & FRDL there is no risk. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of the indicator is normal, under the circumstances. In the case of the companies in the group the indicator shows a good collection of receivables.

4) The value of the **No. of storage Days** indicator can be considered as falling within the specifics of the activity.

Chairman of the Board of Administrators

"TARUS" Valentin Norbert TARUS e.U.

by representative
Valentin-Norbert TARUS

NOTE 5 - Reporting on activity segments

Consolidated		Hospitals & Clinics	Distribution	REMEDIA Pharmacies E-commerce	Services provided And rents	BD ROWA Robots	TOTAL * 30.09.2026
Net turnover		**148.231.137**	**373.630.716**	**7.623.332**	**5.142.139**	**1.951.939**	**536.579.265**
	Income from the sale of goods	148.231.137	375.475.808	7.623.332	0	1.155.018	**532.485.297**
	Commercial discounts granted	0	1.845.092	**0**	0		**-1.845.092**
	Income from services provided and rents			**0**	5.142.139	796.921	**5.939.060**
Other operating income		0	186.947	**36.005**	45.567		**268.519**
OPERATING INCOME - TOTAL		**148.231.137**	**373.817.664**	**7.659.337**	**5.187.706**	**1.951.939**	**536.847.784**
Expenses with goods		**143.104.910**	**341.221.060**	**6.104.129**	**0**	**761.950**	**491.192.049**
	Expenses regarding goods	158.470.548	346.656.498	6.137.983		761.950	**512.026.980**
	Commercial discounts received	-15.365.639	-5.435.439	-33.854	0		**-20.834.931**
Gross margin from sales of goods		**5.126.227**	**32.596.604**	**1.555.208**	**5.187.706**	**393.068**	**45.655.734**
							0
Other operating costs		**4.326.710**	**30.846.802**	**3.295.719**	**1.501.061**	**1.563.246**	**41.533.538**
	Direct costs	3.246.017	21.389.605	2.541.726	1.181.118	1.465.649	**29.824.116**
	Logistics costs	473.351	4.208.093	**47.335**			**4.728.779**
	Indirect costs	607.342	5.249.105	706.658	319.942	97.597	**6.980.643**
OPERATING EXPENSES - TOTAL		**147.431.620**	**372.067.862**	**9.399.847**	**1.501.061**	**2.325.196**	**532.725.587**
							0
Operating result		**799.517**	**1.749.802**	**-1.740.510**	**3.686.645**	**-373.257**	**4.122.197**
Financial result							**1.465.058**
Gross result							**5.587.256**
	Profit tax						-2.713.878
Net profit							**2.873.379**

NOTE 6 – CAPITALS CHANGES

Consolidated	Share capital	Legal reserves	Revaluation reserves	Other reserves	Employee benefits granted in the form of equity instruments	Other equity components	Share premiums	Retained earnings	Current result	Own shares	**TOTAL 2026**
Balance on 01.01.2026	9.548.082	2.122.356	30.526.554	15.603.926	68.708	-3.737.321	757.485	18.105.957	8.038.123	-1.423.835	**79.610.034**
Restoration of profit account								-4.585.670	4.585.670		**0**
Profit transfer 2025 (FR) to retained								7.067.746	-7.067.746		**0**
Profit distribution 2025(FR) to				0				-4.694.314			**-4.694.314**
Profit distribution 2025(FR) to other				2.373.431				-2.373.431			**0**
Account closure 129											**0**
Profit transfer 2025(FRDL) to								5.556.047	-5.556.047		**0**
Profit distribution 2025(FRDL) to								-3.500.000			**-3.500.000**
Profit distribution 2025(FRDL) to				0							**0**
Accounting result 2026 FR + FRDL									5.091.354		**5.091.354**
Profit account retreatment								2.217.975	-2.217.975		**0**
Buildings + lands outputs			0								**0**
Revaluation of buildings and lands											**0**
Transfer reserves from funds											**0**
Reported results - retreating								-59.545			**-59.545**
Buy own shares											**0**
Deferred tax											**0**
Retreatment of operational leasing								-30.568			**-30.568**
Investments in jointly controlled											**0**
Losses from the free transfer of own										0	**0**
Transfer of deferred tax from the											**0**
Accounting adjustments								-65.117			**-65.117**
Reserves – employee share plan (IFRS					576.846						**576.846**
Balance on 30.09.2026	**9.548.082**	**2.122.356**	**30.526.554**	**17.977.357**	**645.553**	**-3.737.321**	**757.485**	**17.639.080**	**2.873.378**	-1.423.835	**76.928.690**

NOTE 7 TREASURY FLOWS STATEMENT (RON)

Consolidated	**30/09/2026**
Cash flows from operating activities	
Collections from the sale of goods and from the provision of services	605.900.267
Other cash inflows	22.536.618
Payments to suppliers of goods and services	-578.133.126
Payments to and on behalf of employees (incl. taxes on salaries)	-17.019.513
Corporate tax payments	-4.089.023
Payments to other taxes and fees	-34.629.595
Paid interests	0
Collected interests (current account)	1.118.416
Other cash outflows	-822.019
Total operating cash flow	**-5.137.976**
Cash flow from investment activities	0
Proceeds from the sale of long-term assets and financial investments	6.937
Collected interests (from deposits)	0
Collected dividends	78.468
Payments for the purchase of long-term assets	-1.918.322
Total cash flow from investments	**-1.832.917**
Cash flow from financing activities	**-4.294.155**
Short-term loan withdrawals	0
Repayment of short-term loans	0
Net foreign exchange differences	15.845
Funding received from shareholders	0
Repayments of long-term loans, including interest	0
Payments to shareholders (dividends)	-4.310.000
Payments of own shares	0
Loans granted between subsidiaries	
Total cash flow from financing	**-4.294.155**
Total cash flow	**-11.265.048**
Cash at the beginning of the period	**57.938.876**
Cash at the beginning period of the associat	
Cash at the end of the period	**46.673.828**

Farmaceutica REMEDIA S.A.
Chairman of the Board of Administrators
"TARUS" Valentin Norbert TARUS e.U.

by representative
Valentin-Norbert TARUS

Remedia
Farmaceutica REMEDIA S.A.



3rd Quarter 2026 UNCONSOLIDATED REPORT

Board of Administrators of
Farmaceutica REMEDIA S.A.

Farmaceutica REMEDIA S.A.
Registered office: Deva 330040, Nicolae Balcescu Bld. no 2 (former No. 43 Dorobantilor Street), Hunedoara County, Telephone: + 40 254 223 260, Fax: +40 254 226 197
Branch office: Bucharest, 041836, sector 4, Bld. Metalurgiei 78, Telephone/fax: + 40 213 211 640
remedia@remedia.ro, www.remedia.ro
Trade Register J1991000700203, TIN: RO2115198; Share capital: RON 9.548.082
IBAN: RO61 BTRL RONC RT00 G713 3302, Transilvania Bank, Bucharest
IBAN: RO33 RZBR 0000 0600 0266 5747, Raiffeisen Unirii, Bucharest

3rd QUARTER 2026 REPORT - unconsolidated
According to F.S.A. Regulation No. 5/2018
Date of the report: 18.11.2026

Name of the commercial company: **Farmaceutica REMEDIA S.A.**

Subscribed share capital: **9.548.082 Lei**
Paid-up share capital: **9.548.082 Lei**
Registered office: **DEVA, No. 2 Nicolae Bălcescu Bd.**, pc **330160**
Tel./fax.: **+40 254 223 260, +40 254 226 197**
No. and date of registration with the Trade Register Office: **J1991000700203**
Tax registration number: **RO2115198**

Securities: **RMAH shares**
(**Registration certificate No. AC-1470-7/17.06.2021**)
Type: **Common Nominative**
Date of registration: **17.03.1997**
Nominal value: **0,10 Lei**
Position in RNSC Register: **1636**
Total number: **95.480.820**
R.N.S.C. code of shares: **16368**

Registration	Date	Number of shares	Issue value
1	10.11.1999	3.370.107	337.010.70 Lei
2	06.09.2001	1.500.000	150.000,00 Lei
3	23.07.2003	42.402	4.240,20 Lei
4	05.01.2006	5.696.471	569.647,10 Lei
5	21.12.2007	87.905.969	8.790.596,90 Lei
6	08.04.2009	7.574.851	757.485,10Lei
7	09.06.2021	- 10.608.980	- 1.060.898,00 Lei
	TOTAL	**95.480.820**	**9.548.082,00 Lei**

Organised market on which securities are traded:
Bucharest Stock Exchange – Standard category
The total market value on 18.11.2026 is of 77.912.349 Lei, at a value of 0,816 Lei/RMAH share

1. Important events to report

During the reporting period, Remedia completed the installation of two pharmacy robots in Jibou and Beius. As a result, the company's own technical team has now installed and commissioned a total of 26 units, consolidating the company's position as the national leader in the automation of pharmacies, warehouses and hospital facilities.

In July 2026, Remedia signed a market maker contract with IFB Finwest SA, with the aim of increasing the liquidity of financial instruments by facilitating buying and selling transactions at a reduced spread, and of enhancing the visibility and attractiveness of the financial instrument to investors.

2. The general description of the financial position and of the issuer's performances and of its branches related to the 3rd quarter 2026

During the period 01.01.2026 – 30.09.2026 the commercial company Farmaceutica REMEDIA S.A. recorded the following financial results:

Crt. No.	Indicator	Realisations Jan-Sept 2026 (Lei)	Realisations Jan-Sept 2025 (Lei)	Evolution 2026/2025 (%)
1.	Net sales of goods *	1.665.264	4.349.666	-61,72%
2.	Other operating revenues	4.807.012	5.864.029	-18,03%
3.	Total operating revenues	6.472.277	10.213.695	-36,63%
4.	Total operating costs *	6.533.836	8.410.864	-22,32%
5.	Operating result	-61.560	1.802.831	-103,41%
6.	Financial result	2.992.030	2.416.945	23,79%
7.	Gross result (profit)	2.930.470	4.219.776	-30,55%

* Including commercial discounts granted/received

"Other operating revenues" mainly comprise the following categories of revenues:

- collected rents – 82%
- BD Rowa services – 17%

3. The financial statements as at 30.09.2026 were not audited by the independent financial auditor.

4. Economic-Financial Indicators

LIQUIDITY AND WORKING CAPITAL	**30.09.2026**
Current liquidity (Current assets / Current debts)	7,92
Current assets	19.048.753
Current debts	2.404.962

Degree of indebtedness (Borrowed capital / Equity x 100)	**0,00%**
Borrowed capital	0
Equity	58.151.695
Turnover speed for client debit items (Average customer balance /turnover *270)	**116 days**
Average customer balance	2.758.567
Net turnover	6.426.710
Turnover speed of stocks (average stock balance/cogs) *270	**55 days**
Average stock balance	242.139
Net COGS	1.191.862

Notes:

[1)] **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the company is capable of covering its short-term debts based on the receivables and cash availability.

[2)] **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. The 0% value indicates that the company has no financing or liquidity problem.

[3)] **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of 116 days is a normal one under the circumstances.

[4)] The value of the **Nr. Of the Storage Days** indicator (55 days), can be considered as falling within the specifics of the activity.

18.11.2026

Board of Administrators

Chairman
"TARUS" Valentin-Norbert TARUS e.U.
1020 Viena, Leopold-Moses Gasse, 4/42/6, Austria

FN 349134h/23.07.2010

Farmaceutica REMEDIA SA

STATEMENT OF COMPREHENSIVE INCOME - unconsolidated (Lei)

	30.09.2026	30.09.2025
Net turnover	**6.426.710**	**8.555.294**
Income from the sale of goods	1.665.264	4.349.666
Commercial discounts granted	0	0
Income from services provided and rents	4.761.446	4.205.628
Income from real estate investments	0	
Other operating income	**45.567**	**1.658.401**
OPERATING INCOME - TOTAL	**6.472.277**	**10.213.695**
Expenses with materials	**1.560.375**	**3.343.613**
Expenses regarding goods	1.191.862	3.043.707
Commercial discounts received	0	0
Expenses with raw materials and consumables	236.768	176.908
Other expenses with materials (inventory objects)	37.105	17.851
Energy and water expenses	94.639	105.147
Expenses with personnel	**2.767.077**	**1.860.545**
Salaries and allowances	1.752.692	1.396.210
Expenses with insurance and social protection	75.289	68.864
Other personnel expenses	939.096	395.471
Amortisations and provisions	**679.474**	**1.050.766**
Amortisations	1.024.434	1.050.496
Net provisions	-344.971	0
Losses from receivables	11	270
Other operating expenses	**1.526.911**	**2.155.939**
Expenses on external services	1.056.353	1.192.454
Expenses with other taxes, charges and assimilated payments	367.775	378.738
Other expenses	102.783	584.747
OPERATING EXPENSES - TOTAL	**6.533.836**	**8.410.864**
OPERATING RESULT	**-61.560**	**1.802.831**
Financial income	**3.003.528**	**2.489.696**
Interest income	420.730	477.326
Income from exchange rate differences	4.330	12.370
Income from dividends	2.578.468	2.000.000
Advance payment discounts	0	0
Other financial income	0	0
Financial expenses	**11.498**	**72.751**
Interest expense		
Operational leasing interest	1.625	1.780
Expenses from exchange rate differences	9.873	70.971
Discounts collected in advance	0	
Other financial expenses		
FINANCIAL RESULT	**2.992.030**	**2.416.945**
TOTAL INCOME	**9.475.805**	**12.703.391**
TOTAL EXPENSES	**6.545.335**	**8.483.615**

GROSS RESULT	**2.930.470**	**4.219.776**
Profit tax	135.898	383.579
TOTAL NET PROFIT of which distributable	**2.794.572**	**3.836.197**
Shareholders of the company	**2.794.572**	**3.836.197**
Minority interest		
Other elements of comprehensive income		
Revaluation of tangible assets		
Tax related to other elements of comprehensive income		
Minority interest		
COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of which a	**2.794.572**	**3.836.197**
Shareholders of the company	**2.794.572**	**3.836.197**
Minority interest		
Earnings per share (in Lei)		
- basic	0,0293	0,0402
- diluted	0,0293	0,0402

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin – Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF FINANCIAL POSITION - unconsolidated (Lei)

	30.09.2026	31.12.2025
ASSETS		
Fixed assets	**46.098.093**	**46.778.298**
Tangible assets	10.861.072	11.605.109
Real estate investments	34.234.480	34.234.480
Operational leasing assets	25.780	28.477
Software licences	97.979	130.449
Pharmacy licences	0	0
Participations held in group companies	602.200	602.200
Participations held in companies outside the group	130.286	130.286
Investments in jointly controlled entities accounted for using the equity method		
Deposits and guarantees paid	146.297	47.297
Current assets	**19.048.753**	**20.533.682**
Stocks	1.258.030	794.467
Advances granted for the purchase of inventories	3.336	2.063
Trade receivables	2.346.036	3.772.937
Other receivables	247.194	494.814
Cash and cash equivalents	15.194.157	15.469.401
Accrued expenses	**233.818**	**115.420**
TOTAL ASSETS	**65.380.664**	**67.427.400**
EQUITIES AND DEBTS		
Equities	**58.151.695**	**59.539.707**
Share capital	9.548.082	9.548.082
Share premiums	757.485	757.485
Reserves	19.565.761	17.192.330
Revaluation reserves	29.140.569	29.140.569
Current result	2.794.573	7.067.746
Retained earnings	1.045.020	1.045.019
Retained earnings - retreatment	-405.950	-340.833
Profit distribution	0	0
Own shares	-1.316.108	-1.316.108
Losses related to the issuance, redemption, sale, free transfer or cancellation of equity instruments	-107.727	-107.727
Employee benefits in the form of equity instruments	645.553	68.708
Other equity items	-3.515.563	-3.515.563
Long-term debts	**4.824.007**	**4.820.834**
Debts from long term operational leasing	27.531	24.358
Provisions		
Debts with deferred income tax	4.796.476	4.796.476
Current debts	**2.404.962**	**3.066.858**
Bank loans	0	0
Debts from financial leasing	0	0
Debts from operational leasing	757	6.121
Suppliers and other similar debts	223.953	700.592
Provisions	0	344.971
Current tax debts	109.064	470.324

Other short-term debts	1.815.600	1.289.262
Deferred income tax liabilities	255.588	255.588
Total debts	**7.228.969**	**7.887.692**
TOTAL EQUITIES AND DEBTS	**65.380.664**	**67.427.400**

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin – Norbert TARUS

NOTE 1 INFORMATION ABOUT THE COMPANY

Farmaceutica REMEDIA S.A. (« the Company ») is a commercial company with registered office in Deva, No. 2 Nicolae Balcescu Bld. (former Str. Dorobantilor 43), Hunedoara County, Romania.

On **July 25th 1991**, it was established as a commercial company with fully state-owned capital by reorganisation of Oficiul Farmaceutic Deva.

On **October 13th 2000**, V. TARUS RoAgencies S.R.L. purchased from FPS the majority shares package (55,802%).

On **January 1st 2006**, Farmaceutica REMEDIA S.A. merged by absorption with V. TARUS RoAgencies S.R.L.

According to Law 95/2006, republished in August 2015, companies were prohibited from carrying out, at the same time, wholesale and retail distribution of medicines. (Art. 800 paragraph 2). Therefore,

On **January 1st 2016** Farmaceutica REMEDIA S.A. completed the transfer to Farmaceutica REMEDIA Distribution & Logistics S.R.L., a new company, 100% owned, of the wholesale distribution activities of medicines together with related activities (logistic services, registration of pharmaceutical products, promotion and marketing of medicines, etc.), Farmaceutica REMEDIA S.A. kept the operation of the chain of pharmacies and local offices.

In **April 2022**, Farmaceutica REMEDIA SA purchased a 50% participation in the share capital of the Romanian legal entity PHARMA EXPERTSPEDITION S.R.L., with registered office in Bucharest, Bd. Metalurgiei, nr. 130E, Sector 4, registered at the Commercial Register of Bucharest with nr. J40/20206/2005, with TIN 18178346, in order to develop and strengthen the distribution and logistics activity.

In **January 2025**, Farmaceutica REMEDIA SA (FR) acquired 24 per cent of the share capital of SC Novoengrama SRL, a company specialising in medical rehabilitation, which operates in the city of Cluj-Napoca.

In this context, **on 30.09.2026** Farmaceutica REMEDIA S.A. held a majority participation (100%) in the company Farmaceutica REMEDIA Distribution & Logistics S.R.L. and a 50% participation in the company PHARMA EXPERTSPEDITION S.R.L.

During the first nine months of 2026 Farmaceutica REMEDIA S.A. did not participate in mergers.

During the same period, the company did not alienate assets of significant value (buildings, land, shares, etc.).

During the reporting period, Remedia completed the installation of two pharmacy robots in Jibou and Beius. As a result, the company’s own technical team has now installed and commissioned a total of 26 units, consolidating the company’s position as the national leader in the automation of pharmacies, warehouses and hospital facilities.

In July 2026, Remedia signed a market maker contract with IFB Finwest SA, with the aim of increasing the liquidity of financial instruments by facilitating buying and selling transactions at a reduced spread, and of enhancing the visibility and attractiveness of the financial instrument to investors.

NOTE 2 BASES FOR DRAFTING THE FINANCIAL STATEMENTS

The financial statements of the company were drafted in compliance with the provisions of Order No. 2844/2016 for the approval of the Accounting regulations in compliance with the International Financial Reporting Standards (IFRS), adopted by the European Union, applicable to commercial companies whose securities are admitted to trading on a regulated market, with all subsequent modifications and clarifications.

For the purpose of drafting these financial statements, in compliance with the legislative provisions in Romania, the functional currency of the company is considered to be the Romanian Leu (RON).

For all the periods until the year concluded on 31 December 2011, inclusive, the company prepared the financial statements in compliance with the Romanian Accounting Standards (RAS). The financial statements for the year concluded on 31 December 2012, are the first financial statements drafted in compliance with the International Financial Reporting Standards (IFRS), as adopted by the European Union.

The financial statements were drafted based on the historic cost, except for the buildings and lands which are assessed at their fair value (the market value determined by assessment by an expert evaluator). The historic cost is generally based on the fair value of the counter-performance carried out in exchange for the assets.

The company presents in the financial statements at the fair value all the asset and passive elements for which the assessment at the fair value is imposed, the methods used for its establishment being inventory and revaluation (IFRS 13).

The company does not have financial statements which would involve the use of other fair value estimation methods.

Certain amounts from the financial position statement, the global result statement, as well as from the explanatory notes were reclassified to ensure comparability between previous years and the current year.

Preparation of the IFRS financial statements involves the use by the management of professional judgments, estimations and hypotheses that may affect the application of the accounting policies and the reported value of assets, debts, incomes and expenses. Under these conditions, the actual results may differ from the estimated values. Estimates and hypotheses that are based on them are periodically reviewed. The review of accounting estimates is recognised during the period in which the estimate was reviewed and in the future periods affected. The following are critical professional judgments / reasoning which the Company management made with a significant impact on the values recognized in the financial statements:

- Lifespan of fixed assets
- Deferred taxes
- Provisions
- Segment reporting

The company holds participations in other companies, within which it has control over the financial and operational policies. An entity is consolidated if, based on the assessment of its relations with the Company, it is found that it is controlled by the Company.

Starting with 2012, for the class of tangible assets « Lands and buildings », the Company passed from the cost-based accounting model to the reassessment model.

The financial statements on 30.09.2026 were not audited by the independent financial auditor.

NOTE 3 SALES REVENUES AND OTHER OPERATING REVENUES

În During the period 01.01.2026 – 30.09.2026, the commercial company Farmaceutica REMEDIA S.A. recorded the following financial results:

Crt. No.	Indicator	Realisations Jan-Sep 2026 (Lei)	Realisations Jan-Sep 2025 (Lei)	Evolution 2026/2025 (%)
1.	Net sales of goods *	1.665.264	4.349.666	-61,72%
2.	Other operating revenues	4.807.012	5.864.029	-18,03%
3.	Total operating revenues	6.472.277	10.213.695	-36,63%
4.	Total operating costs *	6.533.836	8.410.864	-22,32%
5.	Operating result	-61.560	1.802.831	-103,41%
6.	Financial result	2.992.030	2.416.945	23,79%
7.	Gross result (profit)	2.930.470	4.219.776	-30,55%

* Including commercial discounts granted/received

"Other operating revenues" mainly comprise the following categories of revenues:
- collected rents – 82%
- BD Rowa services - 17%

NOTE 4 ECONOMIC-FINANCIAL INDICATORS

LIQUIDITY AND WORKING CAPITAL	**30.09.2026**
Current liquidity (Current assets / Current debts)	7,92
Current assets	19.048.753
Current debts	2.404.962
Degree of indebtedness (Borrowed capital / Equity x 100)	**0,00%**
Borrowed capital	0
Equity	58.151.695
Turnover speed for client debit items (Average customer balance /turnover *270)	**116 days**
Average customer balance	2.758.567
Net turnover	6.426.710

Turnover speed of stocks (average stock balance/cogs)*270	**55 days**
Average stock balance	242.139
Net COGS	1.191.862

Notes:

[1] **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the company is capable of covering its short-term debts based on the receivables and cash availability.

[2] **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. The 0% value indicates that the company has no financing or liquidity problem.

[3] **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of 116 days is a normal one under the circumstances.

[4] The value of the **Nr. Of the Storage Days** indicator (55 days), can be considered as falling within the specifics of the activity.

Chairman of the Board of Administrators
"TARUS" Valentin Norbert TARUS e.U.

by representative
Valentin-Norbert TARUS

NOTE 5 - Reporting on activity segments

Unconsolidated		Remedia	BD Rowa / Robots	Rents for	Provided	TOTAL *
		farmacies		spaces/auto	services	2026
Net turnover		**510.246**	**1.951.939**	**3.964.464**	**60**	**6.426.710**
	Income from the sale of goods	510.246	1.155.018			**1.665.264**
	Commercial discounts granted	**0**		0	0	**0**
	Income from services provided and rents	**0**	796.921	3.964.464	60	**4.761.446**
Other operating revenues		**0**			45.567	**45.567**
OPERATING REVENUES - TOTAL		**510.246**	**1.951.939**	**3.964.464**	**45.627**	**6.472.277**
						0
Expenses with goods		**429.912**	**761.950**	**0**	**0**	**1.191.862**
	Expenses regarding goods	429.912	761.950	0	0	**1.191.862**
	Commercial discounts received	0		0	0	**0**
Gross margin from sales of goods		**80.334**	**393.068**	**0**	**0**	**473.402**
						0
Other operating costs		**456.601**	**1.563.246**	**3.322.089**	**39**	**5.341.974**
	Direct costs	128.822	1.465.649	775.341	0	**2.369.812**
	Logistics costs	**0**		0	0	**0**
	Promotion costs	**0**		0	0	**0**
	Indirect costs	327.779	97.597	2.546.748	39	**2.972.162**
OPERATING EXPENSES - TOTAL		**886.513**	**2.325.196**	**3.322.089**	**39**	**6.533.836**
Operating result		**-376.267**	**-373.257**	**642.376**	**45.588**	**-61.560**
Financial result						**2.992.030**
Gross result						**2.930.470**
	Profit tax					135.898
Net profit						**2.794.572**

NOTE 6 – CAPITALS CHANGES

Unconsolidated	Share capital	Legal reserves	Revaluation reserves	Other reserves	Employee benefits granted in the form of equity instruments	Other equity components	Share premiums	Retained earnings	Current result	Own shares	TOTAL 2026
Balance on 01.01.2026	**9.548.082**	**2.121.796**	**29.140.569**	**15.070.534**	**68.708**	**-3.515.563**	**757.485**	**704.186**	**7.067.746**	**-1.423.835**	**59.539.707**
											0
Profit transfer 2025 to retained								7.067.746	-7.067.746		**0**
Profit distribution 2025 to				0				-4.694.314			**-4.694.314**
Profit distribution 2025 to other				2.373.431				-2.373.431			**0**
Profit distribution 2025 to legal											**0**
Result 2026									2.794.573		**2.794.573**
Legal reserve 2025											**0**
Account closure 129											**0**
Buildings + lands outputs											**0**
Revaluation of buildings and											**0**
Deferred tax											**0**
Transfer reserves from funds				**0**				0			**0**
Buy own shares											**0**
Losses from the free transfer of										0	**0**
Transfer of deferred tax from											**0**
Reserves – Employee Share				0	576.846						**576.846**
Accounting adjustments								-65.117			**-65.117**
IFRS restatement											**0**
Balance on 30.09.2026	**9.548.082**	**2.121.796**	**29.140.569**	**17.443.965**	**645.553**	**-3.515.563**	**757.485**	**639.070**	**2.794.572**	**-1.423.835**	**58.151.695**

NOTE 7 TREASURY FLOWS STATEMENT (RON)

Unconsolidated

	30/09/2026
Cash flows from operating activities	
Collections from the sale of goods and from the provision of services	10.219.904
Other cash inflows	52.407
Payments to suppliers of goods and services	-5.067.286
Payments to and on behalf of employees (incl. taxes on salaries)	-1.681.807
Corporate tax payments	-534.235
Payments to other taxes and fees	-1.722.636
Paid interests	
Collected interests (current account)	420.730
Other cash outflows	-224.154
Total operating cash flow	**1.462.923**
Cash flow from investment activities	
Proceeds from the sale of long-term assets and financial investments	0
Collected interests (from deposits)	
Collected dividends	2.578.468
Payments for the purchase of long-term assets	
Total cash flow from investments	**2.578.468**
Cash flow from financing activities	
Short-term loan withdrawals	
Repayment of short-term loans	0
Net foreign exchange differences	-6.635
Funding received/granted	
Repayments of long-term loans, including interest	
Payments to shareholders (dividends)	-4.310.000
Payments of own shares	0
Loans granted between subsidiaries	
Total cash flow from financing	**-4.316.635**
Total cash flow	**-275.244**
Cash at the beginning of the period	**15.469.401**
Cash at the end of the period	**15.194.157**

Chairman of the Board of Administrators
"TARUS" Valentin Norbert TARUS e.U.

by representative
Valentin-Norbert TARUS

Deva, November 18th 2026

Statement of November 18th, 2026 of responsible persons within the company Farmaceutica REMEDIA S.A. for the 3rd Quarter 2026 Report

In accordance with the legal provisions in force regarding the issuers and the operations with securities, the undersigned, as a responsible person within Farmaceutica REMEDIA S.A., according to our knowledge, declare the following:

1. Unconsolidated and consolidated quarterly financial statements of Farmaceutica REMEDIA S.A. ended September 30, 2026, for the 3rd quarter of the year 2026, prepared according to the applicable accounting standards, gives a correct image and in accordance with the reality of the assets, liabilities, financial position and profit and loss account.
2. The reports of the Board of Administrators include a correct analysis of the issuer's development and performances as well as a description of the main risks and uncertainties specific to the activity carried out.

Function	Name	Period of responsibility
Chairman of the Board of Administrators	„TARUS" - Valentin Norbert TARUS e.U", reprezentata de Valentin-Norbert TARUS	01.01.2026-30.09.2026
General Director	Roxana-Georgiana ULMEANU	01.05.2026-30.09.2026
Member of the Board of Administrators	Cristian PLOCON	01.01.2026-30.09.2026
Member of the Board of Administrators	Theodor COJOCARU-TOTH	01.05.2026 – 30.09.2026